RxDoctor Payments Data

Roy Aaron, MD

Orthopaedic Surgery · East Providence, RINPI 1336189661

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $36,875 of the $37,238 with a category attached, or 99.0%. Zimmer Biomet accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $23,393 and has fallen 99.6% since, to $105 in 2025.

$37,238in general payments, 2019–2025

Across 8 payments — averaging $4654.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$37K
  • Orthofix Medical, Inc.$143
  • Amgen$90
  • Radius Health, Inc.$26
$69,420in research payments, 2019–2025

Across 5 payments — averaging $13,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orthofix Medical, Inc.$56K
  • Zimmer Biomet$14K

What the payments were for

  • Consulting fees$36,87599%
  • Food & beverage$3631%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Zimmer Biomet5$36,980
Orthofix Medical, Inc.1$143
Amgen1$90
Radius Health, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,238 in reported general payments places this provider in the 85th percentile of 124 orthopaedic surgery providers in Rhode Island.

See all orthopaedic surgery providers in Rhode Island

Medicare billing

Part B allowed, 2024
$44,058
Medicare patients
212
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide21$59,083
Risedronate Sodium270$18,939
Risedronate Sodium DrRisedronate Sodium18$6,284
Alendronate Sodium198$1,656
Meloxicam46$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$26$59,08321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 orthopaedic surgery providers in Rhode Island.

Other orthopaedic surgery in East Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →